Adaptimmune Therapeutics logo

ADAP - Adaptimmune Therapeutics News Story

$3.95 -0.2  -5.5%

Last Trade - 18/06/21

Sector
Healthcare
Size
Mid Cap
Market Cap £467.0m
Enterprise Value £238.5m
Revenue £2.61m
Position in Universe 3369th / 6919

Adaptimmune to Present First Preclinical Data from its HLA-independent TCR (HiT) Platform at ASGCT

Tue 27th April, 2021 9:30pm
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20210427:nGNXbm8017&default-theme=true


PHILADELPHIA and OXFORDSHIRE, United Kingdom, April 27, 2021 (GLOBE NEWSWIRE)
-- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to
treat cancer, will report initial preclinical data from its HLA Independent
TCR (HiT) targeting mesothelin, being co-developed with Astellas, during a
poster presentation at the American Society for Cell and Gene Therapy (ASGCT)
meeting. Abstracts were published online today, and data will be updated
during the conference.
* Abstract Title: In vitro selection and engineering of a human leukocyte
antigen-independent T-cell receptor recognizing human mesothelin (Abstract #
641)
* Poster Presentation: Tuesday May 11, 2021 8:00 a.m. - 10:00 a.m. EDT during
the Cancer - Immunotherapy, Cancer Vaccines Session
About Adaptimmune
Adaptimmune is a clinical-stage biopharmaceutical company focused on the
development of novel cancer immunotherapy products for people with cancer. The
Company’s unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell
platform enables the engineering of T-cells to target and destroy cancer
across multiple solid tumors.

Forward-Looking Statements
This release contains “forward-looking statements” within the meaning of
the Private Securities Litigation Reform Act of 1995 (PSLRA). These
forward-looking statements involve certain risks and uncertainties. Such risks
and uncertainties could cause our actual results to differ materially from
those indicated by such forward-looking statements, and include, without
limitation: the success, cost and timing of our product development activities
and clinical trials and our ability to successfully advance our TCR
therapeutic candidates through the regulatory and commercialization processes.
For a further description of the risks and uncertainties that could cause our
actual results to differ materially from those expressed in these
forward-looking statements, as well as risks relating to our business in
general, we refer you to our Annual Report on Form 10-K filed with the
Securities and Exchange Commission (SEC) on February 25, 2021 and our other
SEC filings. The forward-looking statements contained in this press release
speak only as of the date the statements were made and we do not undertake any
obligation to update such forward-looking statements to reflect subsequent
events or circumstances.

Adaptimmune Contacts:

Media Relations:

Sébastien Desprez — VP, Communications and Investor Relations
T: +44 1235 430 583
M: +44 7718 453 176
Sebastien.Desprez@adaptimmune.com

Investor Relations:

Juli P. Miller, Ph.D. — Senior Director, Investor Relations
T: +1 215 825 9310
M: +1 215 460 8920
Juli.Miller@adaptimmune.com


(https://www.globenewswire.com/NewsRoom/AttachmentNg/f61dc272-2f81-43b4-97ce-b387507030db)



GlobeNewswire, Inc. 2021
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.